

UCSF

UC San Francisco Previously Published Works

Title

Non-criteria manifestations in primary antiphospholipid syndrome: a French multicenter retrospective cohort study

Permalink

<https://escholarship.org/uc/item/4tn8v089>

Journal

Arthritis Research & Therapy, 24(1)

ISSN

1478-6354

Authors

Guédon, Alexis F

Catano, Jennifer

Ricard, Laure

et al.

Publication Date

2022-12-01

DOI

10.1186/s13075-022-02726-9

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

RESEARCH ARTICLE

Open Access



Non-criteria manifestations in primary antiphospholipid syndrome: a French multicenter retrospective cohort study

Alexis F. Guédon^{1†}, Jennifer Catano^{1†}, Laure Ricard¹, Charlotte Laurent¹, Claire de Moreuil², Geoffrey Urbanski³, Sophie Deriaz⁴, Grigorios Gerotziafas⁵, Ismail Elalamy⁵, Alexandra Audemard⁴, Francois Chasset⁶, Sonia Alamowitch⁷, Jérémie Sellam⁸, François Maillot⁴, Jean Jacques Boffa⁹, Ariel Cohen¹⁰, Noémie Abisorr¹, Olivier Fain¹ and Arsène Mekinian^{1*}

Abstract

Background: From this retrospective study, we aimed to (1) describe the prevalence and characteristics of non-criteria features in primary antiphospholipid syndrome (p-APS) and (2) determine their prognostic value.

Methods: This retrospective French multicenter cohort study included all patients diagnosed with p-APS (Sydney criteria) between January 2012 and January 2019. We used Kaplan-Meier and adjusted Cox proportional hazards models to compare the incidence of relapse in p-APS with and without non-criteria manifestations.

Results: One hundred and seventy-nine patients with p-APS were included during the study time, with a median age of 52.50 years [39.0; 65.25] and mainly women ($n = 112$; 62.6%). Among them, forty-three patients (24.0%) presented at least one non-criteria manifestation during the follow-up: autoimmune cytopenias ($n = 17$; 39.5%), Libman Sachs endocarditis ($n = 5$; 11.6%), APS nephropathy ($n = 4$; 9.3%), livedo reticularis ($n = 8$; 18.6%), and neurological manifestations ($n = 12$; 27.9%). In comparison to p-APS without any non-criteria manifestations ($n = 136$), p-APS with non-criteria features had more arterial thrombosis ($n = 24$; 55.8% vs $n = 48$; 35.3%; $p = 0.027$) and more frequent pre-eclampsia ($n = 6$; 14.3% vs $n = 4$; 3.1%; $p = 0.02$). The prevalence of triple positivity was significantly increased in patients with non-criteria features ($n = 20$; 47.6% vs $n = 25$; 19.8%; $p = 0.001$). Patients with p-APS and non-criteria manifestations ($n = 43$) received significantly more additional therapies combined with vitamin K antagonists and/or antiaggregants. Catastrophic APS (CAPS) tended to be more frequent in p-APS with non-criteria features ($n = 2$; 5.1% vs none; $p = 0.074$).

The p-APS with non-criteria manifestations had significantly increased rates of relapse ($n = 20$; 58.8% vs 33; 33.7%; $p = 0.018$) in bivariate analysis, but in survival analyses, the hazard ratio (HR) of relapse was not significantly different between the two groups (HR at 1.34 [0.67; 2.68]; $p = 0.40$).

*Correspondence: arsene.mekinian@aphp.fr

†Alexis F. Guédon and Jennifer Catano contributed equally to this work.

¹ AP-HP, Hôpital Saint-Antoine, Service de Médecine Interne and Inflammation-Immunopathology-Biotherapy Department (DMU 3iD), Sorbonne Université, F-75012 Paris, France

Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Conclusions: The presence of non-criteria features is important to consider, as they are associated with particular clinical and laboratory profiles, increased risk of relapse, and need for additional therapies. Prospective studies are necessary to better stratify the prognosis and the management of p-APS.

Keywords: Antiphospholipid antibodies, Antiphospholipid syndrome, Non-criteria antiphospholipid syndrome

Background

Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by vascular thrombosis, pregnancy morbidity, and persistent antiphospholipid antibodies (APL). The classification Sydney criteria consider the arterial and venous thromboses, with or without adverse obstetrical features of APS [1]. Several other features, called non-criteria manifestations, can be associated with thrombotic and obstetrical APS features [2]. These non-criteria manifestations include immune thrombocytopenia and autoimmune hemolytic anemia, livedo reticularis, Libman Sachs endocarditis, APS nephropathy, and neurological manifestations such as migraine, chorea, and longitudinal myelitis. Although these non-criteria manifestations are not specific to primary APS, some studies suggest that their presence could be associated with an increased risk of thrombosis and could be thus defined as a “high risk” APS subtype [3, 4]. Large data about primary APS (p-APS) with non-criteria manifestations and their prognostic value remain understudied. Studies about the prevalence of these various “non”-criteria” APS in p-APS and their various management remain to be better described.

From this retrospective study, we aimed to (1) describe the prevalence and characteristics of non-criteria features in a multicenter cohort of patients with p-APS and (2) determine their prognostic value in comparison to p-APS without any non-criteria features regarding overall and relapse-free survivals.

Methods

Study design

All patients diagnosed with a p-APS (Sydney criteria) between January 2012 and January 2019 from departments of internal medicine, rheumatology, nephrology, neurology, dermatology, cardiology, and hematology of Saint Antoine and Tenon hospitals from Paris and university hospitals of Brest and Tours were included in this retrospective French multicenter cohort study. Patients with systemic lupus erythematosus (SLE) or other systemic autoimmune diseases were excluded. All data, including clinical, laboratory, and treatment variables, were collected by a clinician from the medical records during the first in-hospital contact and considered as baseline parameters. The presence of non-criteria manifestations was recorded as follows: immune thrombocytopenia

and/or autoimmune hemolytic anemia, livedo reticularis, Libman Sachs endocarditis, APS nephropathy, and neurological disorders among multiple sclerosis-like disease, chorea, and seizure. Migraine was considered as a non-criteria manifestation if associated with another non-criteria feature and/or abnormal magnetic resonance imaging. These features were extracted from various centers’ data in a homogeneous standardized file by LR and CL and checked by AM. Combined APS patients include patients with both thrombotic APS phenotype and obstetrical APS phenotype. An ethical committee was not required for this observational study according to Helsinki law and the French institutional committee.

Statistical analysis

Descriptive analyses were expressed as proportions (%) for categorical variables and medians with ranges for continuous variables. First, we compared phenotypes from all p-APS patients with and without non-criteria manifestations, using the non-parametric Fisher test (for qualitative variables) and the non-parametric Wilcoxon test (for quantitative variables). We used Kaplan-Meier and adjusted Cox proportional hazards models to compare the incidence of relapse in p-APS with and without non-criteria manifestations. Sex, vitamin K antagonists, and triple APL positivity status were considered as potential confounders according to the literature [5, 6]. Proportional hazards assumptions were tested based on analysis of Schoenfeld residuals and no interaction was found between variables. Data were imputed for missing data using a multiple imputation technique. A two-sided p value <0.05 was considered as significant. p values have not been adjusted for multiple testing and should not allow inference interpretation. All analyses were performed using R software 3.6.0 version for Mac (Foundation for Statistical Computing, Vienna, Austria).

Results

Prevalence of non-criteria manifestations

One hundred and seventy-nine patients with p-APS were included during the study time, with a median age of 52.50 years [39.0; 65.25] and mainly women ($n = 112$, 62.6%). Among them, forty-three patients (24.0%) presented at least one non-criteria manifestation during the follow-up (Table 1). These non-criteria manifestations were autoimmune cytopenias ($n = 17$; 39.5%)

Table 1 Non-criteria manifestations among primary APS patients

Total number = 43	Autoimmune cytopenia	APS nephropathy	Libman-Sachs endocarditis	Neurological non-criteria	Livedo reticularis
Number	17 (39.5)	4 (9.3)	5 (11.6)	12 (27.9)	8 (18.6)
Type, <i>n</i>	ITP = 13 AIHA = 1 Evan's syndrome = 3	-	-	Multiple sclerosis-like disease = 4 Migraine = 6 Lymphocytic recurrent meningitides = 1 Seizures = 1	-
Associated non-criteria manifestations	APS nephropathy Livedo reticularis	ITP Livedo reticularis	Migraine Livedo reticularis	Libman-Sachs endocarditis	ITP APS nephropathy Libman-Sachs endocarditis
Thrombotic phenotype (pure), <i>n</i> (%)	10 (58.8)	2 (50.0)	2 (40.0)	9 (75.0)	4 (50.0)
Obstetrical phenotype (pure), <i>n</i> (%)	3 (17.6)	0 (0.0)	0 (0.0)	3 (25.0)	0 (0.0)
Combined APS, <i>n</i> (%)	4 (23.5)	2 (50.0)	3 (60.0)	0 (0.0)	4 (50.0)
Triple positivity, <i>n</i> (%)	10 (58.8)	4 (100.0)	3 (60.0)	3 (25.0)	4 (57.1)
Relapse, <i>n</i> /total <i>n</i> (%)	10/12 (83.3)	4/4 (100.0)	1/5 (20.0)	3/10 (30.0)	4/5 (80.0)

AIHA autoimmune hemolytic anemia, APS antiphospholipid syndrome, ITP immune thrombocytopenic purpura

(immune thrombocytopenia in 13 cases, Evan's syndrome in three cases, and autoimmune hemolytic anemia in one case), Libman Sachs endocarditis ($n = 5$; 11.6%), APS nephropathy ($n = 4$; 9.3%), livedo reticularis ($n = 8$; 18.6%), and neurological manifestations ($n = 12$; 27.9%). Thrombotic APS was the most frequent type of APS associated with non-criteria features ($n = 26$; 60.5%), and combined APS was the most frequent APS phenotype in association with Libman Sachs endocarditis ($n = 3$; 60%).

Biological and clinical profiles of non-criteria p-APS

In comparison to p-APS without any non-criteria manifestations ($n = 136$), p-APS with non-criteria features had more arterial thrombosis ($n = 24$; 55.8% vs $n = 48$; 35.3%; $p = 0.027$) and more frequent pre-eclampsia ($n = 6$; 14.3% vs $n = 4$; 3.1%; $p = 0.02$) (Table 2). Whereas the frequencies of various APL were similar between p-APS with and without non-criteria manifestations, the prevalence of triple positivity was significantly increased in patients with non-criteria features ($n = 20$; 47.6% vs $n = 25$; 19.8%; $p = 0.001$).

Triple-positive p-APS with non-criteria manifestations ($n = 20$) had significantly increased rates of relapses (12 (57%) vs 6 (31%); $p = 0.03$) in comparison to triple-positive APS without non-criteria features ($n = 25$), whereas other characteristics (age, follow-up, type of APS, use of immunosuppressive drugs, and hydroxychloroquine) were not significantly different.

Outcome and management of p-APS with non-criteria manifestations

Patients with p-APS and non-criteria manifestations ($n = 43$) received significantly more additional therapies combined with vitamin K antagonists and/or antiaggregants (Table 2). These additional therapies were mainly hydroxychloroquine ($n = 12$; 31.6% vs $n = 19$; 14.7%; $p = 0.035$) and steroids ($n = 12$; 34.3% vs $n = 18$; 14.4%; $p = 0.016$). During the median follow-up of 5.37 years in p-APS with non-criteria manifestations and 2.95 years in those without any non-criteria features ($p = 0.19$), the death rates were not significantly different between the two groups ($n = 5$; 13.5% vs $n = 5$; 4.9%; $p = 0.17$). While rare, catastrophic APS (CAPS) tended to be a more frequent complication of p-APS with non-criteria features ($n = 2$; 5.1% vs none; $p = 0.074$).

Factors associated with relapse

The p-APS with non-criteria manifestations had significantly increased rates of relapse ($n = 20$; 58.8% vs 33; 33.7%; $p = 0.018$) in bivariate analysis, but in survival analyses, the hazard ratio (HR) of relapse was not significantly different between the two groups (HR at 1.34 [0.67; 2.68]; $p = 0.40$) (Fig. 1). Bivariate analysis of factors associated with relapse showed that relapsing patients had significantly more combined APS profile ($n = 17$; 32.1% vs $n = 4$; 5.1%; $p < 0.001$), a previous history of pre-eclampsia ($n = 7$; 13.7% versus $n = 2$; 2.6%; $p = 0.042$), and more non-criteria features ($n = 20$; 37.7% vs $n = 14$; 17.7%; $p = 0.018$) (Table 3). In multivariate analysis, none

Table 2 APS characteristics and outcomes in patients with and without non-criteria manifestations

	Primary APS with non-criteria manifestations (n = 43)	Primary APS without non-criteria manifestations (n = 136)	p value
Male sex, n (%)	14 (32.6)	53 (39.0)	0.564
Age, years, median [IQR]	53.00 [38.50, 69.50]	52.00 [39.00, 65.00]	0.758
APS features			
Thrombotic phenotype (pure), n (%)	26 (60.5)	86 (63.2)	0.884
Obstetrical phenotype (pure), n (%)	6 (14.0)	22 (16.2)	0.913
Combined APS, n (%)	11 (25.6)	29 (21.3)	0.708
Number of thrombosis, n (%)			0.856
None	7 (16.3)	24 (17.6)	
One	27 (62.8)	79 (58.1)	
Two or more	9 (20.9)	33 (24.3)	
Arterial thrombosis, n (%)	24 (55.8)	48 (35.3)	0.027
Venous thrombosis, n (%)	17 (39.5)	73 (53.7)	0.149
Miscarriages, n (%)	6 (14.3)	13 (9.9)	0.615
Intrauterine deaths, n (%)	6 (14.3)	22 (16.8)	0.886
Prematurity, n (%)	3 (7.1)	7 (5.3)	0.956
IUGR, n (%)	3 (7.1)	7 (5.4)	0.965
Pre-eclampsia, HELLP syndrome, n (%)	6 (14.3)	4 (3.1)	0.020
CAPS, n (%)	2 (5.1)	0 (0.0)	0.074
Cardiovascular risk factors			
Arterial hypertension, n (%)	14 (51.9)	38 (38.4)	0.299
Dyslipidemia, n (%)	8 (29.6)	23 (23.2)	0.666
Tobacco, n (%) = 1 (%)	7 (35.0)	13 (21.3)	0.351
Diabetes mellitus, n (%)	4 (19.0)	8 (12.5)	0.699
Overweight, n (%)	5 (21.7)	25 (31.6)	0.511
Laboratory data			
Anti-cardiolipin IgG, IU, median [IQR]	22.40 [5.00, 57.00]	18.00 [4.90, 63.00]	0.868
Anti-cardiolipin IgG positive, n (%)	24 (57.1)	57 (49.6)	0.509
Anti-cardiolipin IgM, IU, median [IQR]	11.00 [2.00, 53.35]	10.00 [2.20, 38.20]	0.980
Anti-cardiolipin IgM positive, n (%)	17 (43.6)	46 (39.7)	0.807
Anti-β2Gp1 IgG, IU, median [IQR]	17.10 [2.00, 60.00]	4.00 [1.00, 25.00]	0.312
Anti-β2Gp1 IgG positive, n (%)	18 (42.9)	39 (33.6)	0.379
Anti-β2Gp1 IgM, IU, median [IQR]	3.00 [1.00, 19.30]	3.00 [1.00, 29.45]	0.930
Anti-β2Gp1 IgM positive, n (%)	13 (32.5)	36 (31.0)	1.000
LAC, n (%)	19 (63.3)	51 (61.4)	1.000
Triple positivity, n (%)	20 (47.6)	25 (19.8)	0.001
Treatment and outcomes			
Antinuclear antibodies, n (%)	15 (40.5)	22 (23.2)	0.075
Vitamin K antagonists, n (%)	31 (77.5)	81 (64.8)	0.193
Antiplatelet therapy, n (%)	19 (50.0)	58 (45.3)	0.746
Hydroxychloroquine, n (%)	12 (31.6)	19 (14.7)	0.035
Steroids, n (%)	12 (34.3)	18 (14.4)	0.016
Relapse, n/total n (%)	20/34 (58.8)	33/98 (33.7)	0.018
Death, n/total n (%)	5/37 (13.5)	5/103 (4.9)	0.167
Time to relapse, years, median [IQR]	3.58 [1.23, 12.54]	1.71 [0.48, 5.77]	0.260
Follow-up, years, median [IQR]	5.37 [0.96, 11.98]	2.95 [1.09, 7.83]	0.191

APS antiphospholipid syndrome, CAPS catastrophic antiphospholipid syndrome, HELLP hemolysis, elevated liver enzymes, and low platelet count, IUGR intrauterine growth restriction, LAC lupus anticoagulant




Fig. 1 Time to relapse according to non-criteria APS status

of these risk factors was independently associated with the risk of relapse (Table 4).

Discussion

From this cohort of p-APS, the main findings are that (1) p-APS with non-criteria features have an increased prevalence of severe features such as arterial thrombosis and pre-eclampsia, (2) triple positivity is increased in p-APS with non-criteria features, and (3) p-APS with non-criteria features might have a poorer prognosis, as suggested by the increased need for additional therapies.

There is still no clear consensus on the exact definitions of non-criteria APS. A recent consensus paper proposed a classification in four categories, including “clinical non-criteria APS patients,” who were patients presenting non-criteria manifestations and APL positivity fulfilling the classification criteria [7]. The prevalence of non-criteria features in p-APS varies according to the studied cohorts and depends on the inclusion criteria, in particular, the exclusion of associated SLE. In an Italian study on 200 women with p-APS ongoing a pregnancy, 39 (19.5%) had non-criteria manifestations, mainly livedo reticularis, valvulopathy, and autoimmune cytopenias [8]. Among 99 female obstetrical APS patients from the APS ACTION registry, livedo reticularis was present in 35%, thrombocytopenia in 44%, and valvulopathy in 15%, but the

presence of non-criteria features was not associated with the first thrombosis [9]. In the European registry of 1000 p-APS and SLE-associated APS, non-criteria features were commonly observed, including thrombocytopenia (8.7%), livedo reticularis (8.1%), autoimmune hemolytic anemia (4%), valve thickening/dysfunction (4.6%), and epilepsy (3.2%) [10]. The prevalence of these non-criteria features in cohorts of p-APS is still not well-established, and a third of our patients have at least one non-criteria feature in this unselected p-APS cohort without any SLE.

Triple positivity was recently demonstrated as a particular laboratory feature associated with an increased risk of thrombosis and obstetrical relapses and a severe APS course. Patients with APS and triple positivity for aPL are at high risk of developing future thromboembolic events with a cumulative incidence of thrombosis at 12.2% (95% CI, 9.6–14.8) after 1 year, 26.1% (95% CI, 22.3–29.9) after 5 years, and 44.2% (95% CI, 38.6–49.8) after 10 years [5]. Among APL asymptomatic carriers, none of the baseline characteristics was predictive of risk of first thrombosis, and the strongest association was found in triple aPL-positive carriers: odds ratio 3.38 (95% CI 1.24–9.22) [11]. Patients with triple aPL positivity had a higher rate of pregnancy complications, despite the fact that they were more frequently receiving low-dose aspirin with low molecular weight heparin [12].

Table 3 Factors associated with relapse: comparison of patients with and without relapses

	APS patients without any relapse during follow-up (n = 79)	APS patient with relapse during follow-up (n = 53)	p value
Male sex, n (%)	23 (29.1)	21 (39.6)	0.286
Age, years, median [IQR]	53.50 [38.75, 66.25]	60.50 [40.75, 69.25]	0.343
APS features			
Thrombotic phenotype (pure), n (%)	61 (77.2)	33 (62.3)	0.096
Obstetrical phenotype (pure), n (%)	14 (17.7)	4 (7.5)	0.158
Combined APS, n (%)	4 (5.1)	17 (32.1)	<0.001
Number of thrombosis, n (%)			<0.001
None	15 (19.0)	6 (11.3)	
One	53 (67.1)	22 (41.5)	
Two or more	11 (13.9)	25 (47.2)	
Arterial thrombosis, n (%)	28 (35.4)	23 (43.4)	0.461
Venous thrombosis, n (%)	40 (50.6)	32 (60.4)	0.356
Miscarriages, n (%)	10 (13.2)	6 (11.8)	1.000
Intrauterine deaths, n (%)	5 (6.6)	5 (9.8)	0.745
Prematurity, n (%)	4 (5.3)	4 (7.8)	0.830
IUGR, n (%)	1 (1.3)	3 (5.9)	0.362
Pre-eclampsia, HELLP syndrome, n (%)	2 (2.6)	7 (13.7)	0.042
CAPS, n (%)	0 (0.0)	2 (3.8)	0.304
Cardiovascular risk factors			
Arterial hypertension, n (%)	23 (39.0)	13 (41.9)	0.964
Dyslipidemia, n (%)	11 (18.6)	8 (25.8)	0.603
Tobacco, n (%) = 1 (%)	9 (17.0)	7 (35.0)	0.179
Diabetes mellitus, n (%)	9 (15.8)	3 (15.0)	1.000
Overweight, n (%)	7 (15.9)	9 (32.1)	0.185
Non-criteria features			
Non-criteria features, n (%)	14 (17.7)	20 (37.7)	0.018
Number of non-criteria features, median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 1.00]	0.007
Laboratory data			
Triple positivity, n (%)	17 (23.0)	18 (36.7)	0.147
Antinuclear antibodies, n (%)	11 (19.6)	11 (29.7)	0.384
Treatment and outcomes			
Vitamin K antagonists, n (%)	39 (52.7)	45 (90.0)	<0.001
Antiplatelet therapy, n (%)	30 (39.0)	26 (53.1)	0.171
Hydroxychloroquine, n (%)	6 (7.8)	16 (32.7)	0.001
Steroids, n (%)	10 (13.0)	14 (29.8)	0.039
Death, n (%)	5 (13.5)	5 (4.9)	0.167
Follow-up, years, median [IQR]	5.37 [0.96, 11.98]	2.95 [1.09, 7.83]	0.191

APS antiphospholipid syndrome, CAPS catastrophic antiphospholipid syndrome, HELLP hemolysis, elevated liver enzymes, and low platelet count, IUGR intrauterine growth restriction

The increased prevalence of triple-positive APS was also noted near 50% of refractory APS patients from the European retrospective cohort [13]. In our study, near half of APS with non-criteria features presented a triple positivity (versus 20% in those without non-criteria features), conferring risk of severe course and risk of relapse. However, one major limitation of our study was the small size

of our sample with available follow-up date, resulting in low statistical power. This might explain the reason why we do not find any difference between patients with and without non-criteria manifestation in our survival analyses, though the bivariate analysis was significantly different. The not-standardized definition of non-criteria APS features could be another important publication bias.

Table 4 Univariate and multivariate factors associated with relapse

	HR	95% CI (HR)	p value
Univariable Cox model (outcome:relapse)			
APS non-criteria features	1.34	[0.67; 2.68]	0.402
Multivariable Cox model (outcome:relapse)			
APS non-criteria features	1.35141	[0.63623; 2.87052]	0.43334
Male sex	1.39057	[0.7032; 2.74984]	0.34323
Vitamin K antagonists	2.45312	[0.89569; 6.71861]	0.08081
Triple positivity	0.80880	[0.3626; 1.80409]	0.60416

APS antiphospholipid, CI confidence interval, HR hazard ratio

The definition and stratification of risk profile in p-APS are of particular interest, as the management of APS is still mainly based on obstetrical or thrombotic clinical phenotype. Indeed, despite several data about the unfavorable outcome, in particular of triple-positive patients, of p-APS patients with positive antinuclear autoantibodies and lupus-like profile (unpublished personal data) or increased Global Anti-Phospholipid Syndrome Score (GAPPS) score, there is actually no real therapeutic adjustments according to these various prognostic risk factors. The value of additional therapies, in particular in obstetrical APS, has been studied, showing promising results using low-dose steroids, hydroxychloroquine, or plasma exchanges [14, 15]. The value of additional therapies, particularly hydroxychloroquine, as illustrated in our cohort, should be better determined, in the specific subset of patients with non-criteria features [16, 17].

Conclusion

The presence of non-criteria features in p-APS patients is important to consider, as they are associated with particular clinical and laboratory profiles, increased risk of relapse, and need for additional therapies. Prospective studies are necessary to better stratify the prognosis and management of p-APS.

Abbreviations

AIHA: Autoimmune hemolytic anemia; APL: Antiphospholipid; APS: Antiphospholipid syndrome; CAPS: Catastrophic antiphospholipid syndrome; GAPPS: Global Anti-Phospholipid Syndrome Score; HELLP: Hemolysis, elevated liver enzymes, and low platelet count; ITP: Immune thrombocytopenic purpura; IUGR: Intrauterine growth restriction; LAC: Lupus anticoagulant; p-APS: Primary antiphospholipid syndrome; SLE: Systemic lupus erythematosus.

Acknowledgements

None

Authors' contributions

All coauthors participated in the study design and data analysis. AG and AM completed the manuscript, and all coauthors approved the final version.

Authors' information

Done for all coauthors and all acknowledge for the data and manuscript content.

Funding

None

Availability of data and materials

Yes. Arsene Mekinian consented to the full data availability.

Declarations

Ethics approval and consent to participate

An ethical committee was not required for this observational study according to Helsinki law and the French institutional committee. Yes, obtained from patients and coauthors

Consent for publication

Yes, obtained from patients and coauthors

Competing interests

The authors declare that they have no competing interests.

Author details

¹AP-HP, Hôpital Saint-Antoine, Service de Médecine Interne and Inflammation-Immunopathology-Biotherapy Department (DMU 3iD), Sorbonne Université, F-75012 Paris, France. ²Service de Médecine Interne, CHRU de Brest, Brest, France. ³Service de Médecine Interne et Immunologie Clinique, Centre Hospitalier Universitaire d'Angers, Angers, France. ⁴Service de Médecine Interne, Hôpital Tours, Tours, France. ⁵Sorbonne Université, AP-HP, Hôpital Tenon, Service de Hémostase et Hématologie biologique, F-75012 Paris, France. ⁶Sorbonne Université, AP-HP, Hôpital Tenon, Service de dermatologie et vénéréologie, F-75012 Paris, France. ⁷AP-HP, Service des Urgences cérébro-vasculaires, Hôpital Pitié-Salpêtrière, Centre de recherche de Saint Antoine, INSERM, UMRS 938, Sorbonne Université, Paris, France. ⁸Sorbonne Université, AP-HP, Hôpital Saint-Antoine, Service de rhumatologie, F-75012 Paris, France. ⁹Sorbonne Université, AP-HP, Hôpital Tenon, Service de néphrologie, F-75012 Paris, France. ¹⁰Sorbonne Université, AP-HP, Hôpital Saint-Antoine, Service de cardiologie, F-75012 Paris, France.

Received: 12 May 2021 Accepted: 14 January 2022

Published online: 25 January 2022

References

- Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). *J Thromb Haemost*. 2006;4(2):295–306.
- Abreu MM, Danowski A, Wahl DG, Amigo M-C, Tektonidou M, Pacheco MS, et al. The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. *Autoimmun Rev*. 2015;14(5):401–14.
- Sciascia S, Amigo M-C, Roccatello D, Khamashta M. Diagnosing antiphospholipid syndrome: "extra-criteria" manifestations and technical advances. *Nat Rev Rheumatol*. 2017;13(9):548–60.
- Radin M, Ugolini-Lopes MR, Sciascia S, Andrade D. Extra-criteria manifestations of antiphospholipid syndrome: risk assessment and management. *Semin Arthritis Rheum*. 2018;48(1):117–20.
- Pengo V, Ruffatti A, Legnani C, Gresle P, Barcellona D, Erba N, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. *J Thromb Haemost JTH*. 2010;8(2):237–42.
- Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. *Arthritis Care Res*. 2009;61(1):29–36.

7. Pires da Rosa G, Bettencourt P, Rodríguez-Pintó I, Cervera R, Espinosa G. "Non-criteria" antiphospholipid syndrome: a nomenclature proposal. *Autoimmun Rev.* 2020;19(12):102689.
8. Fredi M, Andreoli L, Aggogeri E, Bettiga E, Lazzaroni MG, Le Guern V, et al. Risk factors for adverse maternal and fetal outcomes in women with confirmed aPL positivity: results from a multicenter study of 283 pregnancies. *Front Immunol.* 2018;9:864.
9. de Jesús GR, Sciascia S, Andrade D, Barbhaiya M, Tektonidou M, Banzato A, et al. Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study. *BJOG Int J Obstet Gynaecol.* 2019;126(5):656–61.
10. Cervera R, Serrano R, Pons-Estel GJ, Cervera R, Shoenfeld Y, de Ramón E, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. *Ann Rheum Dis.* 2015;74(6):1011–8.
11. Yelnik CM, Urbanski G, Drumez E, Sobanski V, Maillard H, Lanteri A, et al. Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity. *Lupus.* 2017;26(2):163–9.
12. Lazzaroni M-G, Fredi M, Andreoli L, Chighizola CB, Del Ross T, Gerosa M, et al. Triple antiphospholipid (aPL) antibodies positivity is associated with pregnancy complications in aPL carriers: a multicenter study on 62 pregnancies. *Front Immunol.* 2019;10:1948.
13. Mekinian A, Aljotas-Reig J, Carrat F, Costedoat-Chalumeau N, Ruffatti A, Lazzaroni MG, et al. Refractory obstetric antiphospholipid syndrome: features, treatment and outcome in a European multicenter retrospective study. *Autoimmun Rev.* 2017;16(7):730–4.
14. Mekinian A, Kayem G, Cohen J, Carbillon L, Abisror N, Josselin-Mahr L, et al. Obstetrical APS: is there a place for additional treatment to aspirin-heparin combination? *Gynecol Obstet Fertil Senol.* 2017;45(1):37–42.
15. Aljotas-Reig J. Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management. *Lupus.* 2013;22(1):6–17.
16. Mekinian A, Costedoat-Chalumeau N, Masseur A, Tincani A, De Caroli S, Aljotas-Reig J, et al. Obstetrical APS: is there a place for hydroxychloroquine to improve the pregnancy outcome? *Autoimmun Rev.* 2015;14(1):23–9.
17. Xourgia E, Tektonidou MG. Management of non-criteria manifestations in antiphospholipid syndrome. *Curr Rheumatol Rep.* 2020;22(9):51.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

